* Gossamer Bio Inc GOSS.OQ GOSS.O is expected to show a
rise
in quarterly revenue when it reports results on August 6
(estimated) for the period ending June 30 2024
* The San Diego California-based company is expected to
report
revenue of $114.286 million, according to the mean estimate from
7 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Gossamer Bio Inc is for
earnings of 23 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.
* Wall Street's median 12-month price target for Gossamer
Bio Inc
is $6.00, above its last closing price of $0.89.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.19 -0.19 -0.19 Met -0.5
Jan. 1 2024 -0.19 -0.21 -0.21 Met -1
Sep. 30 2023 -0.24 -0.49 -0.21 Beat 17.8
Jun. 30 2023 -0.48 -0.49 -0.45 Beat 8
Mar. -0.52 -0.53 -0.52 Beat 1.8
31 2023
Dec. 31 2022 -0.62 -0.62 -0.59 Beat
Sep. 30 2022 -0.66 -0.64 -0.65 Missed -2.3
Jun. 30 2022 -0.68 -0.70 -0.74 Missed -5.8
This summary was machine generated August 2 at 23:07 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)